Arkolith/Insider Trading/ARQT/Form 4

Vairavan Latha

SVP Chief Financial OfficerArcutis Biotherapeutics, Inc. (ARQT) · full profile →Form 4 · filed Mar 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$72K
Net Open-Market Flow
-$72K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Sell(S)81$25.91$2K88K
Mar 2, 2026Sell(S)3K$25.16$70K88K
Feb 27, 2026Grant(A)27K—$091K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 27, 2026Grant(A)70K—$070K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-014325) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML